Oncopep Inc., of Boston, started a phase Ib trial evaluating PVX-410, a multi-peptide therapeutic cancer vaccine, in patients with moderate or high-risk for progression smoldering multiple myeloma, an asymptomatic precursor to multiple myeloma. Read More
Aveo Oncology Inc., of Cambridge, Mass., said its development partner, Eusa Pharma Ltd., of Hemel Hempstead, U.K., has submitted its responses to the EMA Day 120 list of questions issued by the Committee for Medicinal Products for Human Use as part of the centralized review process of the marketing authorization application for tivozanib for the first-line treatment of advanced renal cell carcinoma. Read More
SHANGHAI – Innovent Biologics Inc., of Suzhou, has raised $260 million from government-backed and independent investors in what is the largest financing round ever for a private biopharma in China. The deal is also the second largest for the sector globally this year. Read More
LONDON – Kymab Group Ltd. has raised $100 million in a series C round led by new Chinese investors, enabling it to move five antibody programs to the clinic over the next three years, with the first trial commencing in 2017. Read More
After three years of imagining the possibilities, U.S. lawmakers are now wheeling and dealing to get the 21st Century Cures Act signed into law before the 114th Congress fades into the sunset. Read More
Global enrollment is complete in the first of two pivotal trials that will back 2018 regulatory filings for the experimental oral peanut allergy treatment AR101, developed by Aimmune Therapeutics Inc. Top-line data from PALISADE, the first phase III study, is expected in the fourth quarter of 2017. Read More
LONDON – The U.K. has announced that it will continue with preparations to join the new single European patent system that is due to get off the ground next year, despite the referendum vote of June 23 to leave the EU. Read More
Theratechnologies Inc., of Montreal, said it filed and obtained a receipt for a final short-form prospectus for a previously announced underwritten offering of 5.32 million common shares at $3.10 per share for gross proceeds of $16.5 million. Read More
